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The process of cell division is critical to the growth and development of an organism. As a
fertilized egg develops into a mature organism, tissues undergo cellular renewal or commit to terminal
differentiation and leave the cell cycle. Tight regulation of events controlling the cell cycle ensures the
integrity of the genetic information and prevents aberrant or unscheduled cell division [1]. Identifying
the molecular nature of the mechanisms that control the cell cycle is crucial, since dysregulation of
this process can lead to various diseases, including cancer, autoimmunity or degenerative disorders.
However, we are still far from a full understanding of the mechanisms operating in the pathways that
control the cell division cycle. This Special Issue is focused on some of the key players contributing to
the regulation of cellular proliferation and the cell cycle, and how this regulation is altered in stressful
or pathological conditions, such as cancer.
As the cell progresses through the interphase of the cell cycle, all the cellular organelles in addition
to DNA must be duplicated before the correct partitioning into daughter cells. This process is tightly
regulated and probably involves many transcriptional and posttranscriptional networks. However,
how cellular organelles are regulated to duplicate their content and size before cell division is not well
understood. The group led by Dr. Zubiaga presents evidence that genes encoding proteins residing in
the Golgi complex are cell cycle-regulated [2]. Transcription factors of the E2F (E2 Promoter Binding
Factor) and the CREB/ATF (cAMP Response Element-Binding protein/Activating Transcription Factor)
families were found to regulate transcription of the Golgi-specific GOLPH3 (Golgi Phosphoprotein-3)
gene during G0 and G1 phases of the cell cycle through distinct elements present in its promoter.
Interestingly, GOLPH3 levels must be tightly regulated for efficient cell cycle progression, suggesting
that a coordinated action of nuclear and organelle components is necessary for a timely cell cycle.
A key player in cell cycle regulation is c-MYC (Avian Myelocytomatosis Viral Oncogene Homolog),
a transcription factor commonly overexpressed in human tumors. c-MYC overexpression is thought to
disrupt checkpoint control and to promote aberrant cell cycle progression. The specific role of c-MYC in
the functional inactivation of cell cycle inhibitors is reviewed by Dr. León and coworkers [3]. Current
research is unraveling a variety of mechanisms by which c-MYC modulates the levels of the Cyclin
Dependent Kinase Inhibitors 1A (p21CIP1), 2A (p14ARF), 1B (p27KIP1) and 2B (p15INK4B), to promote
cell cycle entry and progression. Some of these c-MYC -mediated mechanisms operate directly at the
transcriptional level through distinct promoter elements, such as the repression of the genes encoding
p15INK4B and p21CIP1, or the activation of the gene encoding p14ARF. Other mechanisms are indirect,
through the regulation of miRNA molecules targeting p21CIP1 or p27KIP1 mRNAs, or mediated by
other transcription factors that directly regulate p14ARF expression. Clearly, overexpression of c-MYC,
a common alteration in cancer, impacts the gene regulatory network of cell cycle inhibitors to promote
cellular proliferation.
In contrast to the well-established oncogenic role of c-MYC, certain regulators of the cell cycle,
such as the mitotic regulator Polo Like Kinase 1 (PLK1), appear to play both oncogenic and tumor
suppressor roles in a context-dependent manner. A review article by Dr. de Cárcer analyzes in detail
the functional complexity of PLK1 [4]. A common consequence of both overexpressing and silencing
PLK1 seems to be the induction of aneuploidy and chromosomal instability, particularly when PLK1
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is overexpressed in combination with other oncogenes. Several PLK1-inhibitory drugs are being
tested in clinical trials. However, given the tumor suppressive activity of PLK1, the author suggests
that PLK1-targeting strategies need to be re-evaluated to define what tumors will truly benefit from
these approaches.
The cell cycle is endowed with a control system that ensures proper cell division. Stressful or
damaging conditions inflicted to cells result in the activation of checkpoints along the cell cycle, which
induce cell cycle arrest until the defects are repaired [5]. Dr. Calabrò and collaborators have now
analyzed the cellular responses to damage induced by oxidative stress [6]. They have gathered evidence
that oxidative stress causes enhanced secretion of YB-1, a multifunctional protein known to accumulate
not only in cytoplasmic stress granules, but also in the nucleus, where it participates in DNA repair.
In its secreted form, however, YB-1 was found to promote G2/M cell cycle arrest of neighboring cells,
a process that was associated with an induction of p21CIP1 expression. The authors conclude that
oxidative stress not only impacts the damaged cell, but it can be propagated to neighboring cells
through paracrine mechanisms involving secreted proteins such as YB-1.
Oxidative stress can be triggered by arsenic trioxide, a first-line chemotherapeutic drug used in
oncological practice [7]. Treatment of breast cancer MCF-7 cells with this compound leads to G2/M
cell cycle arrest and apoptosis, associated with deactivation of MAPK and PI3K survival pathways.
Dr. Mbita and collaborators report in this issue that these processes are accompanied by a complex
regulation of survivin gene expression at the level of mRNA splicing [8]. Survivin is an antiapoptotic
protein involved in cancer development [9]. Several survivin isoforms can be generated though
alternative splicing. Interestingly, one of these isoforms, survivin 2B, is upregulated only when
oxidative stress induces G2/M arrest, but not apoptosis, suggesting that this survivin variant may be
specifically involved in cell cycle arrest.
Inflicting damage to the tumor cells constitutes the main objective of anticancer chemotherapies.
Upon extensive damage, tumor cells respond by inducing apoptosis. However, most chemotherapeutic
agents are not only toxic to tumor cells, but also to normal cells, leading to severe side effects. Many
laboratories are focusing their efforts on screening probiotics, searching for new compounds with
anticancer activity but less overall toxicity. According to the work of Dr. Chung and collaborators in this
issue [10]—p8 protein—a small molecule derived from Lactobacillus, appears to have antiproliferative
activity on colorectal cancer cells, particularly when p8 is expressed ectopically in these cells. p8 is able
to induce p21CIP1 very efficiently and to reduce cycB1/CDK1 protein levels, thereby arresting the cell
cycle in G2/M. The next step for this potential candidate for anticancer gene therapy will be to design
effective vectors for its delivery into tumor cells.
The number of proteins known to play a role in cell cycle regulation continues to rise. Dr. Zhao
and coworkers report the identification of Ankyrin Repeat Domain 45 (Ankrd45) as a novel cell cycle
regulator [11]. Thorough studies in zebrafish embryos and human cell cultures show that Ankrd45 is
required for cell proliferation, since its depletion leads to apoptosis. Ankrd45 is mainly localized to the
cleavage furrow and the midbody during mitosis, suggesting that it is required for cell division in
early and late mitosis. Future research should decipher the mechanism underlying Ankrd45-regulated
mitosis and its potential role in cell cycle control.
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